Most prescription eye drops indicated for treatment of DED reduce inflammation or stimulate tear production to address signs and symptoms of disease, although the exact mechanism of action in DED ...

About Reproxalap Reproxalap is an investigational new drug candidate in development for the treatment of dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology.

The FDA has accepted for review the resubmitted New Drug Application for reproxalap for the signs and symptoms of dry eye disease.

About Reproxalap Reproxalap is an investigational new drug candidate in development for the treatment of dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology.

Aldeyra’s late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of ...

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement ...